Search

Your search keyword '"Brossart P"' showing total 103 results

Search Constraints

Start Over You searched for: Author "Brossart P" Remove constraint Author: "Brossart P" Database Unpaywall Remove constraint Database: Unpaywall
103 results on '"Brossart P"'

Search Results

2. The German Network for Personalized Medicine to enhance patient care and translational research

10. 707TiP Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial

12. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

23. Parameters predicting COVID-19-induced myocardial injury and mortality

24. 749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032

32. OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

33. PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL

34. Antibiotic resistant bacteria and resistance genes in biofilms in clinical wastewater networks

35. The occurrence of antimicrobial substances in toilet, sink and shower drainpipes of clinical units: A neglected source of antibiotic residues

36. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

37. Vascular expression of prostate-specific membrane antigen in renal tumors: Diagnostic and prognostic role

38. Evaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study

39. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

40. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation

43. Karzinoide der Lunge

45. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

46. γ-Glutamyl-Transferase ist ein unabhängiger Biomarker für splanchnische Thrombosen bei Patienten mit myeloproliferativen Neoplasien

47. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group

Catalog

Books, media, physical & digital resources